AstraZeneca Demonstrates Commitment to Patients Living With Amyloidosis at the 2024 International Symposium on Amyloidosis
May 25, 2024
May 25, 2024
WILMINGTON, Delaware, May 25 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on May 23, 2024:
AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26-30, 2024.
AstraZeneca and Ionis will present new subgroup analyses of . . .
AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26-30, 2024.
AstraZeneca and Ionis will present new subgroup analyses of . . .